|
|
Vaccine Detail
|
Recombinant Vaccinia-CEA Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia-CEA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007078
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CEACAM5 - obsolete
gene engineering:
- Type: Recombinant protein preparation
- Description: (Hodge et al., 2008)
- Detailed Gene Information: Click Here.
- Preparation: The vaccine was composed of poxviral vectors that express CEA and 3 T-cell costimulatory molecules: B7-1, ICAM-1, and LFA-3 (CEA/TRICOM) (Hodge et al., 2008).
- Description: This is for Liver Cancer (NCT00081848). A recombinant vaccinia virus encoding carcinoembryonic antigen (CEA). CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers. Attenuated vaccinia virus is a highly effective immunizing agent that evokes both humoral and cell-mediated responses. Vaccination with this agent may evoke a cytotoxic immune response to CEA-expressing cells (NCI04) (Tsang et al., 1995; NCIT_C2809).
|
| Host Response |
|
|
| References |
Hodge et al., 2008: Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park, N.Y.). 2008; 22(9); 1064-1070. [PubMed: 18777956].
NCIT_C2809: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2809]
NCT00081848: [https://clinicaltrials.gov/show/NCT00081848/]
Tsang et al., 1995: Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. Journal of the National Cancer Institute. 1995; 87(13); 982-990. [PubMed: 7629885].
|
|
